• NiaHealth

  Participated · Seed · Jun 2025

  NiaHealth provides an end-to-end proactive health platform combining clinical-grade biomarker testing, integrations with consumer wearables, continuous glucose monitoring, and 1:1 clinician guidance to help members identify and act on health risks before symptoms appear. The company offers HSA-eligible services and is available across provinces including Ontario, Alberta, British Columbia, Manitoba, Saskatchewan, Nova Scotia, New Brunswick, Newfoundland and Labrador, and Prince Edward Island. Since emerging from stealth earlier this year it has built a waitlist of over 12,000 Canadians, is on track to cross 300K+ biomarker tests by year-end, and has grown users ~30% month-over-month driven largely by referrals. Platform 2.0, launching this summer, expands testing from ~50 to 100+ biomarkers, adds toxic heavy metals, omegas and advanced thyroid tests, and deepens wearable and CGM integrations. The company plans continued product R&D into predictive features and development of human-first, AI-supported clinician tools while scaling user expansion across Canada. Partnerships with the University of Alberta and corporate customers like Ada support its scientific research and employer benefits programs.

• PulseMedica

  Participated · Series A · Jul 2024

  PulseMedica is developing an ophthalmic medical-device platform that uses 3D computer vision, real-time tracking, and femtosecond laser technology for non-invasive, automated imaging and treatment of eye floaters and other vitreoretinal disease. The company is advancing a floater imaging device and is conducting laser safety and feasibility studies to enable a first-in-human clinical trial. Recent funding is being used to accelerate clinical validation, support ongoing studies, and expand the technical and business teams in preparation for commercialization and regulatory approvals. Since 2020 PulseMedica has raised over CA$16M, including a CA$6.5M investment from a multinational strategic in 2023; it announced CA$12M raised to date as part of its pre-Series A financing. Product development progress includes seven prototype devices and the filing of 14 patents. PulseMedica is attracting interest from potential lead investors for an upcoming Series A round. PulseMedica is a University of Alberta spinoff building a fully automated platform that images the eye, determines treatment locations, and delivers therapy using lasers instead of injections. The company aims to demonstrate the safety and accuracy of its imaging and laser delivery systems through a first clinical trial beginning in June. That trial will test the system on 10–15 Edmonton patients with diabetic retinopathy. PulseMedica is finishing device build and pursuing Health Canada approvals ahead of the study, and has recently expanded its team and established a medical advisory board of ophthalmologists. The startup is working out of the MNP Tower in downtown Edmonton and plans to move to a larger space this summer. Financially, PulseMedica raised an oversubscribed $2.6M seed round and previously raised $1M in a 2020 pre-seed plus roughly $1M in grants. Once it accumulates clinical data the company expects to pursue a Series A targeting about US$10M, with a goal of making the technology available to clinicians by 2024.

• Nucleos

  Participated · Equity · Nov 2023

  Nucleos offers an all-in-one service that brings web-based educational content and authorized media to correctional facilities via secure tablets. The company handles security, disables components that could enable prohibited outside communication, and tracks courses and credentials for reentry. Nucleos does not manufacture tablets or create course content, but integrates those elements for facilities and partners with in-person educators rather than replacing them. Authorized media available through its library system includes e-books and movies, and the company says it may offer video calling and messaging in the future. Nucleos emphasizes digital literacy training alongside its tools to help incarcerated people use modern interfaces. The organization recently reclassified as a public benefit corporation and runs a “reentry-as-a-service” program supported in part by public funding such as San Francisco’s "People Over Profits" program. To sustain operations while pursuing more facility deals, Nucleos raised private investment and grants. Nucleos has built an online portal for tablets and computer labs in prisons that offers academic coursework, mental‑wellness content and vocational training with an emphasis on credentials that count toward high school or industry certification. Content from 10 companies is available, covering high‑school credit recovery, literacy, typing and job‑related skills; some programs offer industry‑recognized certifications such as NCCER and OSHA. The platform also tracks inmates’ completed programs and certifications to address frequent transfers between facilities. The company is San Jose, Calif.‑based and was founded in 2017; its software is currently used at one juvenile facility while it is in discussions with community colleges and county and state departments of corrections. Nucleos plans to charge correctional facilities directly for access to its software and is working on a partnership with an online course provider that partners with major universities. The team of five has been funded by friends and family, a Princeton alumni fund, a $225,000 NSF grant and recent investor support.

• Arbutus Medical

  Participated · Equity · Feb 2023

  Arbutus Medical develops TrakPak®, a single-use, pre-sterile procedure kit for bedside skeletal traction in trauma center ERs, and distributes surgical drills using its patented DrillCover Technology. The DrillCover creates a sterile enclosure around DEWALT® power tools, converting them into disposable sterile surgical drills and reducing the need for between-case sterilization. The company says its products have regulatory clearances from the U.S. FDA and Health Canada and that its devices have been used in 40 countries, enabling an estimated 85,000 surgeries. Arbutus is ISO13485 certified and aims to expand TrakPak adoption to improve ER efficiency, reduce costs, and broaden access to safe surgical care. The financing announced will fund the launch of the next-generation TrakPak in 2023 and support rapid scale-up. Arbutus Drill Cover, based in Vancouver, BC, develops a sterile cover that turns a hardware-store drill into a surgical tool. The device is intended to enable the use of consumer drills in surgical procedures. Arbutus was one of six Canadian healthtech companies selected for investment by Grand Challenges Canada. Grand Challenges Canada invested $1 million in Arbutus as part of a $5 million package across the six companies. Grand Challenges Canada, funded by the Government of Canada, worked with the companies through its transition-to-scale program to facilitate connections with private partners and public resources to secure additional funding. After each company went through the transition-to-scale program, the total investment reached $10 million.

No current team members are available.